{
    "clinical_study": {
        "@rank": "92585", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV", 
                "arm_group_type": "Experimental", 
                "description": "DCV 3DAA tablet orally twice daily for 12 weeks + Placebo for DCV tablet orally once daily and Placebo for ASV capsule orally twice daily for 24 weeks (Double blind)"
            }, 
            {
                "arm_group_label": "Arm 2: DCV/ASV + Placebo for DCV 3DAA", 
                "arm_group_type": "Active Comparator", 
                "description": "Daclatasvir 60 mg tablet orally once daily and Asunaprevir 100 mg capsule orally twice daily for 24 weeks + Placebo for DCV 3DAA tablet orally twice daily for 12 weeks (Double blind)"
            }, 
            {
                "arm_group_label": "DCV 3DAA", 
                "arm_group_type": "Experimental", 
                "description": "DCV 3DAA (open label) Tablet orally twice daily for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate that the proportion of treatment-naive\n      non-cirrhotic subjects with Genotype (GT)-1b treated with Daclatasvir (DCV)/Asunaprevir\n      (ASV)/BMS-791325 who achieve Sustained Virologic response (SVR12), defined as Hepatitis C\n      virus (HCV) RNA < LOQ target detected or target not detected (LOQ TD/TND) at follow-up Week\n      12, is significantly higher than SVR12 of current Standard of Care (SOC)."
        }, 
        "brief_title": "UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Virus Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Virus Diseases", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Limit of Quantitation (LOQ)\n\n      Ribonucleic acid (RNA)\n\n      End of Treatment (EOT)\n\n      Triple Direct Acting Antivirals (3DAA)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Males and females, \u2265 20 years of age\n\n          -  Subjects chronically infected with HCV GT-1\n\n          -  HCV RNA viral load of \u2265 100,000 IU/mL\n\n        Exclusion Criteria:\n\n          -  Hepatocellular carcinoma\n\n          -  Co-infection with Hepatitis B virus (HBV) or Human immunodeficiency virus (HIV)\n\n          -  Severe or uncontrollable complication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "286", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123654", 
            "org_study_id": "AI443-117"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 2: DCV/ASV + Placebo for DCV 3DAA", 
                "intervention_name": "Daclatasvir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2: DCV/ASV + Placebo for DCV 3DAA", 
                "intervention_name": "Asunaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV", 
                    "DCV 3DAA"
                ], 
                "intervention_name": "DCV 3DAA", 
                "intervention_type": "Drug", 
                "other_name": "Daclatasvir 30 mg /Asunaprevir 200 mg /BMS-791325 75 mg fixed dose combination"
            }, 
            {
                "arm_group_label": "Arm 2: DCV/ASV + Placebo for DCV 3DAA", 
                "intervention_name": "Placebo for DCV 3DAA", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV", 
                "intervention_name": "Placebo for Daclatasvir", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV", 
                "intervention_name": "Placebo for Asunaprevir", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 23, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Treatment-Naive and IFN Experienced Subjects With Genotype 1 Chronic Hepatitis C", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of treated subjects who achieve SVR12 in treatment-naive non-cirrhotic subjects treated with DCV/ASV/BMS-791325, defined as HCV RNA < LOQ target detected or target not detected (LOQ TD/TND) at post-treatment follow-up Week 12", 
            "safety_issue": "No", 
            "time_frame": "After 12 weeks of the last dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123654"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of treatment-naive subjects who achieve SVR12 with DCV/ASV/BMS-791325 or DCV/ASV", 
                "safety_issue": "No", 
                "time_frame": "Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT (week 12 or 24); post-treatment Weeks 4, 8, 12 and 24"
            }, 
            {
                "measure": "The proportion of Interferon (IFN) experienced subjects who achieve SVR12 with DCV/ASV/BMS-791325", 
                "safety_issue": "No", 
                "time_frame": "Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT (week 12 or 24); post-treatment Weeks 4, 8, 12 and 24"
            }, 
            {
                "measure": "The proportion of subjects who achieve HCV RNA < LOQ TD/TND at each of the following Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT; post-treatment Weeks 4 (SVR4), 8 (SVR8) and 24 (SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT (week 12 or 24); post-treatment Weeks 4, 8, 12 and 24"
            }, 
            {
                "measure": "The proportion of subjects who achieve HCV RNA < LOQ TND at each of the following Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT; post-treatment Weeks 4, 8, 12 and 24", 
                "safety_issue": "No", 
                "time_frame": "Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT (week 12 or 24); post-treatment Weeks 4, 8, 12 and 24"
            }, 
            {
                "description": "based on the US National Institutes of Health Division of AIDs (DAIDS) criteria", 
                "measure": "On-treatment safety as measured by the frequency of Serious Adverse Event (SAEs), discontinuations due to Adverse Event (AEs), and selected Grade 3 - 4 laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 48 weeks"
            }, 
            {
                "measure": "The proportion of subjects with anemia defined as Hb < 10 g/dL on-treatment who had Hb  \u2265 10 g/dL at baseline", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 48 weeks"
            }, 
            {
                "measure": "The proportion of subjects in each cohort who achieve SVR12 associated with HCV genotype subtype 1a vs 1b", 
                "safety_issue": "No", 
                "time_frame": "Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT (week 12 or 24); post-treatment Weeks 4, 8, 12 and 24"
            }, 
            {
                "measure": "The proportion of subjects in each cohort who achieve SVR12 associated with IL28B Single Nucleotide Polymorphisms (SNP) status", 
                "safety_issue": "No", 
                "time_frame": "Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT (week 12 or 24); post-treatment Weeks 4, 8, 12 and 24"
            }, 
            {
                "measure": "The proportion of cirrhotic and non-cirrhotic subjects who achieve SVR12", 
                "safety_issue": "No", 
                "time_frame": "Weeks: 1, 2, 4, 6, 8, 12, 16, 20 and 24; EOT (week 12 or 24); post-treatment Weeks 4, 8, 12 and 24"
            }, 
            {
                "measure": "On-treatment safety of non-cirrhotic vs cirrhotic subjects, as measured by the frequency of SAEs, discontinuations due to AEs, and selected Grade 3 - 4 laboratory abnormalities on DAIDS criteria", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 48 weeks"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}